BLPH · Bellerophon Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $16.36M | $13.02M | $17.89M | $11.03M | $20.26M | $17.85M |
| SG&A | $6.02M | $7.15M | $8.39M | $6.44M | $7.62M | $6.75M |
| Total Operating Expenses | $22.38M | $20.16M | $26.28M | $17.47M | $27.88M | $24.60M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($22.38M) | ($20.16M) | ($26.28M) | ($17.47M) | ($27.88M) | ($24.60M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($2.42M) | ($1.80M) | ($2.13M) | ($1.80M) | ($5.44M) | $0 |
| Net Income | ($19.83M) | ($17.76M) | ($24.73M) | ($13.27M) | $2.81M | ($23.81M) |
| EPS - Basic | ($2.08) | ($1.87) | ($3.17) | ($2.95) | ($1.58) | - |
| EPS - Diluted | ($2.08) | ($1.87) | ($3.17) | ($2.95) | ($1.58) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.92M | $24.74M | $47.56M | $9.87M | $16.64M | $28.82M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.23M | $1.19M | $3.73M | $3.11M | $2.75M | $3.85M |
| Current Assets | $7.56M | $25.46M | $48.08M | $10.38M | $17.40M | $35.58M |
| Total Assets | $7.93M | $26.88M | $50.24M | $13.11M | $18.36M | $36.81M |
| Current Liabilities | $5.40M | $5.05M | $10.43M | $7.58M | $7.54M | $7.08M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $5.40M | $5.26M | $11.99M | $9.52M | $14.50M | $39.40M |
| Stockholders' Equity | $2.53M | $21.62M | $38.25M | $3.59M | $3.86M | ($2.59M) |
| Retained Earnings | ($252.08M) | ($232.25M) | ($214.49M) | ($189.76M) | ($176.50M) | ($179.31M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($17.77M) | ($22.82M) | ($19.88M) | ($12.94M) | ($15.49M) | ($17.46M) |
| Investing Cash Flow | - | - | - | $0 | $3.00M | $12.20M |
| Financing Cash Flow | ($40.0K) | - | $57.57M | $6.17M | $166.0K | $13.21M |
| CapEx | - | - | - | - | $0 | $0 |
| Free Cash Flow | - | - | - | - | ($15.49M) | ($17.46M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | -5.51 | 0.73 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -249.9% | -66.1% | -49.2% | -101.2% | 15.3% | -64.7% |
| Return on equity | -782.6% | -82.1% | -64.7% | -369.5% | 73.0% | 918.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.40 | 5.04 | 4.61 | 1.37 | 2.31 | 5.03 |
| Quick ratio | 1.40 | 5.04 | 4.61 | 1.37 | 2.31 | 5.03 |
| Cash ratio | 1.28 | 4.90 | 4.56 | 1.30 | 2.21 | 4.07 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 3.13 | 1.24 | 1.31 | 3.65 | 4.76 | -14.19 |
| Liabilities / Assets | 0.68 | 0.20 | 0.24 | 0.73 | 0.79 | 1.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.0% | 23.3% | -50.4% | 37.3% | -13.3% | -3.5% |
| Net income growth (YoY) | -11.7% | 28.2% | -86.4% | - | - | 0.0% |
| EPS growth (YoY) | -11.2% | 41.0% | -7.5% | -86.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 11.3% | -1.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -88.3% | -43.5% | 965.1% | -6.9% | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Bellerophon Therapeutics against the 5 most active filers in the same SIC group.